KQ Bio released its 2026 interim report. Total operating revenue was 374 million yuan, down 23.28% from the same period last year. Net profit attributable to the parent company was 116 million yuan, down 47.37% year-on-year. Net cash inflow from operating activities was 116 million yuan, down 33.54% year-on-year. The company's latest asset-liability ratio was 10.68%, and gross margin was 59.42%, down 7.86 percentage points from the same period last year. Diluted earnings per share were 0.25 yuan, down 46.81% year-on-year. Total asset turnover was 0.08 times, and inventory turnover was 1.04 times. The company had 9,669 shareholders, and the top ten shareholders held 73.98% of the total share capital.
Wuhan Keqian Biology Co LtdInterim net profit fell 47.37% YoY and revenue dropped 23.28%, with gross margin down 7.86 percentage points.